Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis

NCT01519089 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01519089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01519089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
January 31, 2014
Enrollment
95 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis